Monoclonal antibodies and immunotherapy : theory and applications
| dc.contributor.author | Adam, Albert | |
| dc.date.accessioned | 2024-03-19T15:35:05Z | |
| dc.date.available | 2024-03-19T15:35:05Z | |
| dc.date.issued | 2024 | |
| dc.identifier.uri | http://hdl.handle.net/1866/32800 | |
| dc.subject | Immunotherapy | fr |
| dc.subject | Monoclonal antibodies | fr |
| dc.subject | Antigenic targets | fr |
| dc.subject | Theory and applications | fr |
| dc.title | Monoclonal antibodies and immunotherapy : theory and applications | fr |
| dc.type | Matériel didactique / Educational material | fr |
| dc.contributor.affiliation | Université de Montréal. Faculté de pharmacie | fr |
| dcterms.abstract | This document is an update of a previous one published on the Papyrus site of the University of Montreal in 2023. It takes into account new therapeutic targets as well as monoclonal antibodies approved last year by the FDA. This update consists of two parts. Firstly. the theoretical bases underlying the antigen-antibody reaction and therefore the effectiveness of active and passive immunotherapy. On the other hand, a description and classification of the 70 antigenic targets as well as their 150 corresponding monoclonal antibodies currently used for passive immunotherapy. | fr |
| dcterms.description | Revision and update 2024 | |
| dcterms.hasVersion | https://doi.org/1866/32798 | |
| dcterms.language | eng | fr |
Files in this item
This item appears in the following Collection(s)
This document disseminated on Papyrus is the exclusive property of the copyright holders and is protected by the Copyright Act (R.S.C. 1985, c. C-42). It may be used for fair dealing and non-commercial purposes, for private study or research, criticism and review as provided by law. For any other use, written authorization from the copyright holders is required.